Related Experiment Video
Updated: Jun 16, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
The type I IFN system in rheumatoid arthritis
Paola Conigliaro1, Carlo Perricone, Robert A Benson
1Division of Rheumatology, Universita' degli studi di Roma Tor Vergata, Rome, Italy.
Autoimmunity
|February 20, 2010
Summary
Type I interferons (IFNs) and dendritic cells (DCs) are implicated in rheumatoid arthritis (RA). Research explores their role in autoimmune arthritis and potential therapeutic manipulation for immune tolerance.
Area of Science:
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
- Current RA treatments targeting adaptive or innate immunity are ineffective for many patients.
- Type I interferons (IFNs) are key regulators of the innate immune system with complex roles in RA.
Purpose of the Study:
- To investigate the role of Type I IFNs and dendritic cells (DCs) in the pathogenesis of rheumatoid arthritis.
- To explore the potential of manipulating these cells and their products for therapeutic benefit in RA.
Main Methods:
- Analysis of Type I IFN (IFN-alpha and beta) presence in RA synovial tissues.
- Studies in murine models of arthritis involving manipulation of plasmacytoid dendritic cell (pDC) populations.
- Investigation of DCs as vehicles for therapeutic vaccines in RA.
Main Results:
- Type I IFNs are detected in RA and have shown controversial results in therapeutic approaches.
- Plasmacytoid DCs (pDCs) can suppress arthritis development and autoimmunity in murine models.
- Dendritic cells (DCs) are being explored for therapeutic vaccine delivery in ongoing clinical trials for RA.
Conclusions:
- Type I IFNs and DCs play significant roles in the development of autoimmune arthritis.
- Manipulation of IFNs and DCs presents a promising therapeutic strategy for RA and other T-cell-mediated autoimmune diseases.
- Further research in animal models will clarify the potential for immune tolerance induction through IFN and DC-based therapies.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...